EMA Authorised: Breyanzi (lisocabtagene maraleucel) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA has authorised Breyanzi (lisocabtagene maraleucel) for specified lymphomas, including large B-cell diffuse and follicular lymphoma, under Bristol-Myers …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mediastinal Neoplasms

Drugs mentioned

• Breyanzi (lisocabtagene maraleucel)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Large B-Cell, Diffuse;Lymphoma, Follicular;Mediastinal Neoplasms. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 23/07/2026